Atara Biotherapeutics, Inc. (ATRA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0465132068
Atara Biotherapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 120.77 m USD |
| Operating income | 35.86 m USD |
| EBIT | 36.51 m USD |
| Net income | 32.69 m USD |
| Diluted EPS – continuing operations | 2.57 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
More stocks
- Yusin Holding Corp (4557.TW)
- Green Optics Co., Ltd. (0015G0.KQ)
- Handok (002390.KS)
- Sincerity Applied Materials Holdings Corp (SINC)
- Tungsten West PLC (TUN.L)
- Hyundai C&F Inc (227840.KS)
- BioPorto (BIOPOR.CO)
- Maxiparts Ltd (MXI.AX)
- Daesung Holdin (016710.KS)
- Pengana International Equities Ltd (PIA.AX)
- Simple Mart Retail Co Ltd (2945.TW)
- CPS TECHNOLOGIES CORP/DE/ (CPSH)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.